查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1763905

靜脈鐵劑市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、應用、地區和競爭細分，2020-2030 年）

Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年，全球靜脈注射鐵劑藥物市場規模為24.6億美元，預計2030年將達到33.9億美元，複合年成長率為5.70%。對於無法耐受口服鐵劑或對口服鐵劑反應不佳的患者，靜脈注射鐵劑療法已成為重要的替代療法。在醫院、腫瘤科和透析中心等需要快速補充鐵劑的地區，這種療法越來越受到重視。

市場概覽
預測期 2026-2030
2024年市場規模 24.6億美元
2030年市場規模 33.9億美元
2025-2030 年複合年成長率 5.70%
成長最快的領域 右旋糖酐鐵
最大的市場 北美洲

慢性腎臟病 (CKD)、發炎性腸道疾病 (IBD)、心臟衰竭和癌症等慢性疾病相關貧血的盛行率不斷上升，是推動需求成長的主要因素。更安全的新一代靜脈鐵劑的推出也透過減少不良反應和無需進行試驗給藥，提高了臨床應用率。這些進步，加上醫療保健專業人員意識的不斷提高，正在提升靜脈鐵劑療法在已開發國家和發展中國家醫療保健體系中的吸引力和可及性。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

治療費用高昂

主要市場趨勢

更重視孕產婦和兒童健康

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球靜脈注射鐵藥物市場的影響

第5章：全球靜脈注射鐵劑市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依產品（葡聚醣鐵、葡萄糖酸鐵、蔗糖鐵、羧基麥芽糖鐵、異麥芽糖苷鐵 1000、Ferumoxytol）
    • 依應用（腸道吸收不良症候群、發炎性疾病、胃切除/減重手術、貧血、Osier-Weber-Rendu 病、血管發育不良、懷孕、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美靜脈注射鐵劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲靜脈注射鐵劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區靜脈鐵劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美靜脈注射鐵劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東和非洲靜脈注射鐵劑市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球靜脈注射鐵劑市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • AMAG pharmaceuticals, Inc.
  • Vifor Pharma Management Ltd.
  • Daiichi Sankyo Company, Limited
  • Rockwell Medical Inc.
  • Allergan PLC
  • Pfizer Inc.
  • Nippon Shinyaku Co.
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 5093

The Global Intravenous Iron Drugs Market was valued at USD 2.46 Billion in 2024 and is projected to reach USD 3.39 Billion by 2030, registering a CAGR of 5.70%. Intravenous (IV) iron therapy has emerged as a critical alternative for patients who cannot tolerate or respond inadequately to oral iron supplements. This approach is gaining prominence in hospital settings, oncology departments, and dialysis centers where rapid iron restoration is essential.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.46 Billion
Market Size 2030USD 3.39 Billion
CAGR 2025-20305.70%
Fastest Growing SegmentIron Dextran
Largest MarketNorth America

The growing prevalence of anemia related to chronic conditions such as chronic kidney disease (CKD), inflammatory bowel disease (IBD), heart failure, and cancer is a major factor propelling demand. The introduction of safer, next-generation IV iron formulations has also improved clinical adoption by reducing adverse reactions and eliminating the need for test dosing. These advancements, combined with increasing awareness among healthcare professionals, are enhancing the appeal and accessibility of IV iron therapy in both developed and developing healthcare systems.

Key Market Drivers

Growth in Healthcare Industry

The rapid growth of the global healthcare sector continues to be a fundamental driver of the intravenous iron drugs market. With annual revenues exceeding USD 4 trillion, the healthcare industry includes key segments like pharmaceuticals, biotechnology, and diagnostics-each contributing significantly to the expansion of IV therapies.

Chronic diseases such as CKD, IBD, and cancer are increasingly diagnosed and treated as healthcare infrastructure improves globally. This has elevated the demand for iron supplementation, particularly in cases of iron-deficiency anemia that require immediate and effective intervention. By 2026, the number of hospitals worldwide is projected to reach 215,977, driven primarily by growth in regions like China, the Far East, and parts of Africa and the Middle East. With rising numbers of specialty clinics, diagnostic centers, and infusion-equipped facilities, the uptake of IV iron therapies is becoming more widespread, further fueling market momentum.

Key Market Challenges

High Cost of Treatment

A major hurdle facing the intravenous iron drugs market is the relatively high cost of treatment. Newer formulations such as ferric carboxymaltose and iron isomaltoside entail higher costs than conventional oral supplements. These expenses encompass drug prices, administration services, medical staff, and monitoring post-infusion, especially in hospital or clinic settings.

This cost factor poses a significant barrier in resource-limited countries where public health budgets are constrained. Even in advanced healthcare systems, variations in insurance coverage and high out-of-pocket costs can impede access to IV iron therapies. These economic barriers restrict wider adoption and make cost-containment strategies critical to expanding market reach.

Key Market Trends

Increasing Focus on Maternal and Pediatric Health

A notable trend influencing the intravenous iron drugs market is the growing emphasis on improving maternal and pediatric health outcomes. Iron-deficiency anemia remains prevalent among pregnant women and children, particularly in low- and middle-income countries. Sub-Saharan Africa alone accounts for roughly 70% of global maternal deaths, underlining the urgent need for effective interventions.

IV iron therapy is increasingly recognized as a preferred treatment for moderate to severe anemia during pregnancy, especially when oral supplements prove ineffective. Timely administration helps reduce the risk of complications such as low birth weight, preterm labor, and postpartum hemorrhage. This trend is supported by heightened awareness among healthcare professionals and the inclusion of IV iron in prenatal care protocols, signaling continued market growth in this segment.

Key Market Players

  • AMAG Pharmaceuticals, Inc.
  • Vifor Pharma Management Ltd.
  • Daiichi Sankyo Company, Limited
  • Rockwell Medical Inc.
  • Allergan PLC
  • Pfizer Inc.
  • Nippon Shinyaku Co.
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.

Report Scope

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intravenous Iron Drugs Market, By Product:

  • Iron Dextran
  • Ferric Gluconate
  • Iron Sucrose
  • Ferric Carboxymaltose
  • Iron Isomaltoside 1000
  • Ferumoxytol

Intravenous Iron Drugs Market, By Application:

  • Intestinal Malabsorption Syndromes
  • Inflammatory Diseases
  • Gastrectomy/Bariatric Surgery
  • Anemia
  • Osier-Weber-Rendu Disease
  • Angiodysplasia
  • Pregnancy
  • Others

Intravenous Iron Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intravenous Iron Drugs Market.

Available Customizations

Global Intravenous Iron Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Intravenous Iron Drugs Market

5. Global Intravenous Iron Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol)
    • 5.2.2. By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Intravenous Iron Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Intravenous Iron Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Intravenous Iron Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Intravenous Iron Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Intravenous Iron Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Intravenous Iron Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Intravenous Iron Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Intravenous Iron Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Intravenous Iron Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Intravenous Iron Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Intravenous Iron Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Intravenous Iron Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Intravenous Iron Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Intravenous Iron Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Intravenous Iron Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Intravenous Iron Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Intravenous Iron Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Intravenous Iron Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Intravenous Iron Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Intravenous Iron Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Intravenous Iron Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Intravenous Iron Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Intravenous Iron Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Intravenous Iron Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Intravenous Iron Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. AMAG pharmaceuticals, Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Vifor Pharma Management Ltd.
  • 16.3. Daiichi Sankyo Company, Limited
  • 16.4. Rockwell Medical Inc.
  • 16.5. Allergan PLC
  • 16.6. Pfizer Inc.
  • 16.7. Nippon Shinyaku Co.
  • 16.8. Novartis International AG
  • 16.9. Takeda Pharmaceutical Company Limited
  • 16.10. Bausch Health Companies Inc.

17. Strategic Recommendations

18. About Us & Disclaimer